Researchers from Kexing Biopharm Co. Ltd. have published details on the development and preclinical characterization of GB18-06, a novel nanobody, also known as variable domain of heavy-chain antibody ...

The Japanese government, industry and academia are deliberating health care policies and initiatives to boost Japan’s role in ...

In what seems a replay of concerns about technetium shortages from the 2010s, a bipartisan group of members of the U.S. House ...

Modifi Biosciences Inc. has come a long way very quickly. Spun out of Yale University in 2021, it published data on DNA in ...

Boston Scientific Corp. posted another eye-popping quarterly report, led by a 177% year-over-year increase in its ...

The EU's regulatory crisis continues to roil relations between Brussels and stakeholders in the health care sector, and the ...

Cellbion Co. Ltd. debuted on the tech-heavy Kosdaq board of the Korea Exchange Oct. 16, with share prices closing upward at ...

Grifols SA has entered into a partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to ...

Editas Medicine Inc. has achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell (HSPC) ...

Oblique Therapeutics AB has achieved a milestone within its research project on the Nav1.8 ion channel with the goal of ...

Despite positive findings from an earlier trial, Alto Neuroscience Inc.’s BDNF-targeting candidate, ALTO-100, failed to best placebo in a phase IIb study in major depressive disorder, sending shares ...

Nippon Chemiphar Co. Ltd. has disclosed morphinan derivatives acting as κ-opioid receptor agonists reported to be useful for the treatment of cough, pain, pruritus, substance abuse and dependence, and ...